Executive Management

The management team for Resilience combines extensive experience in the areas of pharmaceuticals, cGMP manufacturing, biologics R&D and process development, business and financial operations, and commercialization.

Peter Khoury, PhD, MBA at Resilience CDMO
Peter Khoury, PhD, MBA at Resilience CDMOPresident and Chief Executive Officer

Dr. Khoury joined Resilience in August 2016 as Senior Vice President and Chief Commercial Officer and was promoted to President and CEO in June 2017. Before joining Resilience, Dr. Khoury was with the Bill & Melinda Gates Foundation, serving as Senior Program Officer, Life Sciences Partnerships, Office of the President for Global Health. Among his responsibilities, he spearheaded the expansion of industry engagement with the developing country manufacturing industry sector, including relationship management at the “C” level for strategically important and complex DCMs focused on life-saving initiatives including vaccines, biologicals, medical diagnostics, and generic products. Prior to his tenure with the Gates Foundation, from 2002 to 2012, Dr. Khoury was Vice President, Global Marketing at Baxter International, where he led the development and implementation of the company’s vaccines business strategies, product management, business plans, and ex-European vaccine sales. Before Baxter, Peter spent 10 years at Merck and Co., Inc. in positions of growing responsibilities in the areas of business development, marketing and sales. Dr. Khoury earned his bachelor’s degree in biology and a PhD in microbiology from Syracuse University, and received his MBA in Management/Marketing from Cornell University’s Johnson Graduate School of Management.
Ron Cobb, PhD at Resilience CDMO
Ron Cobb, PhD at Resilience CDMOChief Scientific Officer

Dr. Cobb joined Resilience in 2011. As Chief Scientific Officer, Dr. Cobb is responsible for the development of novel vaccines, biologics, and medical devices. He also works to help procure outside funding for the company’s strategic programs. During his tenure at Resilience, Dr. Cobb has led project teams focused on recombinant protein-based drug and vaccine development as well as medical device development. Prior to joining Resilience, he was Director of Research and Development at RTI Biologics. Under his leadership, over 20 new products and line extensions were launched and a stem cell-based technology was initiated. He also spent 7 years as Head of the Protein Expression and Purification Group at Berlex Biosciences (subsidiary of Schering, AG).

Dr. Cobb has over 20 years of experience in biopharmaceutical and medical device research and development and has provided molecular biology expertise to numerous projects ranging from early stage research to supporting protein expression and purification for a Phase 2 clinical program. He has over 40 peer-reviewed publications and book chapters and has been a reviewer for several different journals for over 10 years.

James M. Matthew at Resilience CDMO
James M. Matthew at Resilience CDMOChief Financial Officer

Mr. Matthew joined the Resilience Board of Directors in February 2008 and became the chief financial officer of the company in March 2011. Mr. Matthew is a member of the board of managers of NANO ADM, LLC, a wholly-owned subsidiary of the company, of which he became president and chief executive officer in May 2016. Mr. Matthew has over 40 years of financial experience, including more than 20 years as the chief financial officer of public and private companies with responsibilities for accounting, finance, information management, investor relations, procurement, and facility services. In addition, he had 20 years of experience with KPMG, where he was responsible for a variety of transactions and financings for the Health Care and Life Sciences Industry Group. Mr. Matthew received a Master of Biotechnology Enterprise and Entrepreneurship from Johns Hopkins University, a Master of Business Administration from Michigan State University and a Bachelor of Arts in Accounting and Auditing from the University of Illinois.
Brandon Brega at Resilience CDMO
Brandon Brega at Resilience CDMOChief Operating Officer

Mr. Brega joined Resilience in 2019 and leads manufacturing and operations. With nearly 25 years of experience, including, plant management and technical operations. His depth of expertise in vaccine and biological manufacturing, in particular, and his proven track record of achieving efficient operations, has been refined across multiple organizations by realizing improved operational performance and overall product quality.

Prior to joining Resilience, Mr. Brega served in various positions at Merck & Co., most recently at the company’s Durham, North Carolina location – the largest vaccines only facility in Merck’s network. Prior to joining Merck, Mr. Brega worked for several animal health manufacturers including Pfizer, Wyeth, Boehringer Ingelheim and Merial leading operations and technical organizations in the production of vaccines, biologics and sterile injectables. He has broad base of experience with both drug substance and drug product manufacturing across both small and large molecules.

Bärbel Eppler, PhD at Resilience CDMO
Bärbel Eppler, PhD at Resilience CDMOSenior Vice President, Quality and Regulatory

Dr. Eppler joined Resilience in April 2001 as Director of the Bioanalytical Department, was promoted to VP of Preclinical Development and QA in 2006, Senior VP of Preclinical Development and Quality Assurance in 2008, and Chief Quality Officer in 2015. Prior to joining Resilience, she held a postdoctoral traineeship from 1999 to 2001 at the University of Florida. Dr. Eppler received a BS in zoology and a PhD in pharmaceutical sciences from the University of Florida. During her tenure at Resilience, Dr. Eppler has created and fully implemented from ground zero a robust Quality Assurance and Compliance program that has been successfully audited by several biologic, pharmaceuticals, and medical device companies as well as regulatory agencies such as the FDA. She led the quality team to obtain ISO 13485 and 9001 certification in 2012. Dr. Eppler provides leadership and technical contributions at Resilience, directing preclinical and analytical departments to complete tasks for contracts and grants and regulatory submissions for biologic medical devices and pharmaceuticals.
Robert V. House, PhD, FATS at Resilience CDMO
Robert V. House, PhD, FATS at Resilience CDMOSenior Vice President, Government Contracts

Dr. House joined Resilience in June 2014 as Senior VP of Government Contracts. Previously, Dr. House worked for more than 11 years at DynPort Vaccine Company in Frederick, Md., where he held the positions of VP of Science and Technology, Chief Scientific Officer and President. During this time he developed extensive experience in winning and managing large USG-funded programs for developing medical countermeasures. He previously worked at Covance Laboratories in Madison, Wis. and IIT Research Institute in Chicago, Ill., where he managed highly successful programs in immunotoxicology assessment.

Dr. House has nearly 30 years’ experience in basic and applied biomedical research and development, specializing in the assessment of inadvertent and therapeutic immunomodulation. Dr. House earned a BA in zoology and an MSPH and PhD from the University of North Carolina at Chapel Hill. He is the author/ co-author of more than 100 journal articles and 28 book chapters and editor of two books in the fields of immunomodulation, immunotoxicology, host defense, cytokine biology and biodefense.

Dr. House is an adjunct professor at George Mason University where he teaches graduate courses in medical countermeasure development. He is a fellow of the Academy of Toxicological Sciences.

Timothy Cooke, PhD, MBA at Resilience CDMO
Timothy Cooke, PhD, MBA at Resilience CDMOSenior Vice President, Commercial Business

Dr. Cooke has broad leadership experience in both emerging and large multinational companies in the fields of vaccines and immunotherapeutics including Merck Vaccines, Sanofi Pasteur-MSD, Mojave Therapeutics and Avant Immunotherapeutics. He was most recently CEO of NovaDigm Therapeutics, a privately-held biotechnology company developing vaccines and immunotherapeutics against Candida and Staphylococcus aureus. Dr. Cooke was appointed to represent the biotechnology industry on the National Vaccine Advisory Committee of the U.S. Department of Health and Human Services for 2015-2019. He is an expert on vaccines against antimicrobial-resistant pathogens and currently serves on the Advisory Board of CARB-X. He was a member of the Incentives for Vaccines Working Group of the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria in 2017. He is a member and previous Co-Chair of the Biotechnology Innovation Organization’s Vaccine Policy Advisory Committee and a member of BIO’s Antimicrobial Resistance Working Group. He has a B.S. in Chemistry from St. Joseph’s University and a Ph.D. in bioorganic chemistry and M.B.A. from Columbia University.